Bold new criteria for tracking ATTR-CM progression emerge from a multinational expert panel, aiming to refresh the 2021 framework with clearer thresholds and recommended monitoring intervals. In a recent JACC: Heart Failure Position Statement, Pablo García-Pavía, MD, PhD, and Matthew S. Maurer, MD, FACC, along with colleagues, propose six key parameters to guide ongoing assessment of transthyretin amyloid cardiomyopathy (ATTR-CM) progression. These parameters are: heart failure–related hospitalization, outpatient diuretic intensification, NT-proBNP levels, estimated glomerular filtration rate (eGFR), the six-minute walk test (6MWT), and quality of life as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) or the New York Heart Association (NYHA) functional class.
The authors define disease progression as meeting the thresholds for at least two of these six indicators. While each parameter carries prognostic value, relying on a single metric could overstate disease advancement. Therefore, the proposed approach emphasizes a composite view rather than a one-size-fits-all signal.
A key methodological point is to perform assessments annually and compare current results to the prior 12 months, rather than to baseline values or to a span of 12 months that might include random fluctuations. This helps avoid misclassifying short-term variability as true progression.
García-Pavía and colleagues attribute the proposed update to several drivers: new data underscoring the prognostic relevance of specific ATTR-CM parameters, growing awareness among cardiologists, and advances in diagnostic techniques that collectively support a more nuanced monitoring framework.
Looking ahead, the authors encourage future studies to determine whether changes in disease-modifying therapies for ATTR-CM translate into improved outcomes for patients who show progression under these criteria.
Clinical Topics: Heart Failure and Cardiomyopathies; Acute Heart Failure
Keywords: Quality of Life, Disease Progression, Cardiomyopathies, Heart Failure, Amyloidosis
Controversy invite: How might these thresholds influence treatment decisions across diverse patient populations, and should thresholds be tailored to individual risk profiles or comorbidities? What are the potential implications of deeming progression based on two of six metrics in clinical practice? Share your thoughts in the comments.
